Unlabelled: Rheumatoid Arthritis (RA) has been associated with anemia. The treatment of anemia in RA includes blood transfusions, erythropoietic agents and iron supplements. Our observations suggest that the treatment of the inflammatory disease is associated with an improvement of hemoglobin (Hgb) levels in RA patients.
Methods: Record review, analyzing anemic RA patients and hemoglobin level changes after intensification of RA therapy. Three initial regimes were identified: corticosteroid (Prednisone), Disease Modifying Anti-rheumatic Drugs (DMARD's) plus Prednisone and for patients with no initial treatment with the initiation of Prednisone and or TNF a inhibitors (Etanercept).
Results: 8 female and 2 male patients with average age 59.7 + 14 years were selected. The results for the group treated with Prednisone initially N=4; showed a 0.9 g/dL increase in Hgb and Hct increase of 3% after addition of Etanercept. Those with DMARDs and corticosteroid regime had an Hgb and Hct increase of 1.2 g/dL and 3.5% after addition of Etanercept. The group with no initial treatment was further divided in two groups. The first was treated with Etanercept and the second was treated with Prednisone, resulting in average Hgb increases of 1.9 g/dl Hgb and 1.8 g/dL, and HCT increase 4% and 3.9% respectively. The global average change in Hgb was 1.3g/dL and HCT increase 3.2%.
Conclusion: The intensity of treatment of RA including Etanercept and Prednisone improved cases of mild anemia in rheumatoid arthritis.
Download full-text PDF |
Source |
---|
Atractylenolide I (ATL-I) can interfere with Colorectal cancer (CRC) cell proliferation by changing apoptosis, glucose metabolism and other behaviors, making it an effective drug for inhibiting CRC tumor growth. In this paper, we investigated the interactions between ATL-I and Keratin 7 (KRT7), a CRC-specific marker, to determine the potential pathways by which ATL-I inhibits CRC development. The KRT7 expression level in CRC was predicted online using the GEPIA website and then validated.
View Article and Find Full Text PDFCancers (Basel)
December 2024
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy.
Background/objectives: Hematopoietic cell transplantation (HCT) is a curative treatment for various hematological diseases but can lead to complications which increase malnutrition risk, particularly in allogeneic transplantation patients. This study evaluates the nutritional status evolution of patients undergoing HCT during hospitalization and follow-up.
Methods: This retrospective observational study included 365 patients, divided into two groups: 134 underwent allogeneic HCT, while 231 underwent autologous transplantation or CAR-T therapy.
Plants (Basel)
January 2025
Jilin Provincial Key Laboratory of Plant Resource Science and Green Production, Jilin Normal University, Siping 136000, China.
The growing depletion of the ozone layer has led to increased ultraviolet B (UV-B) radiation, prompting plants like the alpine Pall. () to adapt to these harsh conditions. This study explored how abscisic acid (ABA) signaling influences 's metabolic responses under UV-B stress.
View Article and Find Full Text PDFSupport Care Cancer
January 2025
Department of Medical Oncology, Heidelberg University Hospital and National Center for Tumor Diseases Heidelberg, a partnership between German Cancer Research Center (DKFZ) and University Medical Center Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.
Purpose: Physical performance is crucial for prognosis after allogeneic hematopoietic stem cell transplantation (allo-HCT). Cardiorespiratory fitness has already been shown to have prognostic value, and there is increasing evidence that muscle strength and associated parameters (e.g.
View Article and Find Full Text PDFJ Pediatr Surg
December 2024
Division of Pediatric Surgery, Department of Surgery, University of Florida, Gainesville, FL, USA. Electronic address:
Introduction: Neonatal postoperative outcomes may be negatively affected by perioperative red blood cell transfusion (RBCT). This study compared 30-day postoperative outcomes between transfused and non-transfused neonates.
Methods: The National Surgical Quality Improvement Program (NSQIP) Pediatric dataset (2021-2022) was used to analyze the association between RBCT and 30-day morbidity and mortality after neonatal surgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!